Lorenzo Gerratana, Associate Professor of Medicine and Scientific Lead for Breast Medical Oncology at the CRO Aviano National Cancer Institute and the University of Udine, shared a post on LinkedIn:
“We are excited to announce that PMAC will be present at SABCS 2025 with a series of high-impact presentations showcasing our collaborative work across liquid biopsy, real-world evidence, and precision oncology.
Poster Spotlight 5 | December 11, 2025 | 7:00–8:30 AM | Hemisfair 3
PD5-05 · I-SURV prospective study: Impact of ctDNA surveillance on quality of life in early-stage breast cancer – Cheng Cheng (UCLA)
Poster Session 2 | December 10, 2025 | 5:00–6:30 PM | Exhibit Hall
PS2-07-04 · Time-to-progression patterns during endocrine therapy and ctDNA-defined mutational profiles in HR+/HER2– MBC – Lorenzo Gerratana (University of Udine)
PS2-09-18 · Methylation-based ctDNA + CTCs in early-stage breast cancer: predictors of response to neoadjuvant therapy – Caterina Gianni (IRST Meldola)
PS2-10-11 · Neighborhood deprivation, CDK4/6 inhibitor use, outcomes, and ctDNA alterations in MBC – Emily Podany (Washington University in St. Louis)
Poster Session 4 | December 11, 2025 | 5:00–6:30 PM | Exhibit Hall
PS4-02-11 · ctDNA-based molecular and prognostic profiling of HR+/HER2+ metastatic breast cancer – Lorenzo Foffano (University of Udine)
PS4-03-26 · cfDNA BRCA copy-number loss/deletions in metastatic breast cancer – Neelima Vidula (Massachusetts General Hospital)
Learn more on the PMAC website.”
More posts from SABCS 2025.